<DOC>
	<DOCNO>NCT00736645</DOCNO>
	<brief_summary>RATIONALE : Selenomethionine may slow growth prostate cancer . Testosterone cause growth prostate cancer cell . Finasteride may fight prostate cancer lower amount testosterone body make . Giving selenomethionine together finasteride surgery radiation therapy may effective treatment prostate cancer . PURPOSE : This randomized phase II trial study well selenomethionine finasteride work give surgery radiation therapy treat patient stage I stage II prostate cancer .</brief_summary>
	<brief_title>Selenomethionine Finasteride Before Surgery Radiation Therapy Treating Patients With Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To investigate effect selenomethionine and/or finasteride key androgen receptor signal biomarkers ( prostate-specific antigen , kallikrein 2 , NKX3.1 ) prostate tissue sample patient stage I II prostate cancer . Secondary - To analyze effect selenomethionine and/or finasteride apoptosis induction benign prostate tissue sample patient . Tertiary - To determine whether responsiveness selenomethionine and/or finasteride related level Prx1 prostate cancer cell . OUTLINE : Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral selenomethionine oral finasteride daily 4-5 week . Patients undergo prostatectomy brachytherapy . - Arm II : Patients receive oral placebo oral finasteride daily 4-5 week . Patients undergo prostatectomy brachytherapy . - Arm III : Patients receive oral selenomethionine oral placebo daily 4-5 week . Patients undergo prostatectomy brachytherapy . - Arm IV : Patients receive two oral placebo daily 4-5 week . Patients undergo prostatectomy brachytherapy . Blood sample collect baseline day prostatectomy brachytherapy . Samples analyze testosterone 5-α-dihydrotestosterone level capillary gas chromatography-mass spectrometry ; genetic polymorphism type 2 5-α reductase gene PCR sequencing analysis ; selenium level atomic absorption spectrophotometry . Additional blood sample store future analysis alpha gamma tocopherol , lycopene , vitamin level . Toenail sample also collect provide indicator long-term selenium status . Prostate tissue sample collect prostatectomy prior brachytherapy . Samples analyze expression biomarkers ( e.g. , prostate-specific antigen , kallikrein 2 , NKX 3.1 ) quantitative RT-PCR apoptosis TUNEL assay , immunohistochemistry , ELISA .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate Diagnosed sextant great biopsy Clinical stage &lt; T3 ( stage I II ) disease Prostatespecific antigen &lt; 20.0 ng/mL Gleason score &lt; 8 Scheduled undergo prostatectomy brachytherapy PATIENT CHARACTERISTICS : Life expectancy &gt; 5 year No prior malignancy ( exclude nonmelanoma skin cancer ) past 5 year Willing able take finasteride , selenomethionine , and/or placebo 35 week prior prostatectomy/brachytherapy PRIOR CONCURRENT THERAPY : More 1 year since prior finasteride , dutasteride , Sereona repens ( saw palmetto ) , 5α reductase inhibitor No prior hormonal therapy radiotherapy More 30 day since prior concurrent participation clinical trial involve medical , surgical , nutritional , lifestyle intervention ( e.g. , dietary modification exercise ) No concurrent selenium dietary supplement dose &gt; 200 mg/day , include multivitamin supplement At least 30 day since &gt; 200mg/day prior selenium dietary supplement No concurrent hormonal therapy , include 5α reductase inhibitor ( e.g. , finasteride dutasteride ) ; antiandrogens ( e.g. , bicalutamide , flutamide , ketoconazole ) ; luteinizing hormonereleasing hormone agonist ( e.g. , leuprolide acetate , goserelin acetate , abarelix )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
</DOC>